title: Review of cost-effectiveness analysis of medical treatment for myocardial infarction.
abstract: OBJECTIVE
  Myocardial infarction (MI) is a leading cause of death in both the industrialized and developing countries globally. The economic evaluation of MI is undertaken to rationale the allocation of scarce healthcare resource. The objective is to review cost-effectiveness analysis of MI with medications.
  
  
  METHODS
  WE SEARCHED PUBMED USING THE KEY WORDS: "cost effectiveness analysis"and "myocardial infarction" After applying the selection criteria, eight articles were selected for the present study.
  
  
  RESULTS
  Out of eight articles, five had studied thrombolytic agents. All of these papers clearly explain the costs and benefits of different drugs for MI. ICER was assessed in six out of the eight articles to compare the costs and health effects between alternative medications. ICER was expressed in different effect units.
  
  
  CONCLUSIONS
  This study found that various medications including thrombolytic agents, ACEI and heparin are administered to treat MI in many countries. It is also found that five of eight studies focus on thrombolytic therapies. It implies that thrombolytic is generally very cost effective for MI to the whole society.
authors: MPH Student, Karolinska Institutet, Sweden.
authors: Yanmei
authors: Y
authors: Liu
authors: Koustuv
authors: K
authors: Dalal
references: BMJ. 1992 Sep 5;305(6853):548-53
references: 1393033
references: Heart. 2008 Jun;94(6):679-84
references: 18480342
references: Expert Opin Pharmacother. 2008 Jan;9(1):95-105
references: 18076341
references: N Engl J Med. 2006 Apr 6;354(14):1477-88
references: 16537665
references: Eur Heart J. 2007 Jul;28(13):1598-660
references: 17569677
references: J Am Coll Cardiol. 2001 Jun 15;37(8):2215-39
references: 11419905
references: N Engl J Med. 1993 Sep 2;329(10):673-82
references: 8204123
references: Arch Mal Coeur Vaiss. 1989 Oct;82 Spec No 3:55-62
references: 2512889
references: Lancet. 1992 Mar 28;339(8796):753-70
references: 1347801
references: Can J Cardiol. 2009 Dec;25(12):e399-405
references: 19960133
references: J Am Coll Cardiol. 2009 Sep 29;54(14):1271-9
references: 19778669
references: Lancet. 1994 May 7;343(8906):1115-22
references: 7910229
references: JAMA. 1992 Mar 25;267(12):1669-75
references: 1542179
references: Eur Heart J. 1998 Oct;19(10):1518-24
references: 9820990
references: N Engl J Med. 1986 Jun 5;314(23):1465-71
references: 2871492
references: Am Heart J. 2005 Apr;149(4):637-44
references: 15990746
references: Am Heart J. 2005 Feb;149(2):217-26
references: 15846258
references: Eur Heart J. 1993 Jan;14(1):75-83
references: 8432296
references: Br Heart J. 1988 May;59(5):527-34
references: 3132962
references: J Am Coll Cardiol. 1999 Sep;34(3):890-911
references: 10483976
references: Eur Heart J. 1992 Jan;13(1):2-8
references: 1577026
references: Lancet. 1988 Mar 12;1(8585):545-9
references: 2894490
references: Pharmacoeconomics. 1998 Mar;13(3):337-46
references: 10178659
references: Ann Intern Med. 1990 Jul 15;113(2):147-54
references: 2113784
references: Clin Cardiol. 1997 Nov;20(11 Suppl 3):III6-10
references: 9422856